New data on the effect of Atacand(R) on NYHA class in a broad spectrum of heart failure patients
...ted measure of symptomatic limitation in CHF. That candesartan has been shown to improve NYHA functional class ac...id: "CHARM was a unique programme which found that candesartan reduced both cardiovascular death and hospital admission in a broad spectrum of heart failure patien...Randomisation phase of the DIRECT programme (DIabetic REtinopathy Candesartan Trials) completed
...h an angiotensin II type 1 (AT1) receptor blocker, candesartan cilexetil, targeting the renin angiotensin system ...ogramme, patients are assigned to receive 32 mg of candesartan cilexetil or placebo. The DIRECT programme, launched on Nov. 1, 2000, is being coordinated through E...Atacand(R) proven to prevent stroke in the elderly
...tients were then randomly assigned to double-blind candesartan or placebo with standard open-label anti-hypertensive therapy added as needed to control blood pressure. 1,518 of these patients had ISH (SBP > 160 and DBP <90 mmHg). "ISH is the predominant form of hypertension in the elderly, with stroke th...CHARM* Programme demonstrates clear benefits of Atacand in the treatment of heart failure
...amme in order to evaluate the clinical benefits of candesartan in the treatment of this debilitating and distress...t failure patients who cannot take ACE inhibitors, candesartan reduces death and hospital admission for heart failure by 23%, which is highly significant". CHARM......programme, currently investigating the efficacy of candesartan cilexetil (Atacand) in heart failure, commented: ...al use of AT1-receptor blockade, and in particular candesartan cilexetil, in patients with heart failure." Professor Karl Swedberg, Professor of Medicine, Gteb...